These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18566690)

  • 61. Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.
    Ammazzalorso A; De Filippis B; Giampietro L; Amoroso R
    ChemMedChem; 2013 Oct; 8(10):1609-16. PubMed ID: 23939910
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Peroxisome proliferator-activated receptors and their ligands: entry into the post-glucocorticoid era of skin treatment?
    Weindl G; Schäfer-Korting M; Schaller M; Korting HC
    Drugs; 2005; 65(14):1919-34. PubMed ID: 16162018
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Peroxisome proliferator-activated receptors: from genes to physiology.
    Kliewer SA; Xu HE; Lambert MH; Willson TM
    Recent Prog Horm Res; 2001; 56():239-63. PubMed ID: 11237216
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Conserved transcriptional activity and ligand responsiveness of avian PPARs: Potential role in regulating lipid metabolism in mirgratory birds.
    Hamilton A; Ly J; Robinson JR; Corder KR; DeMoranville KJ; Schaeffer PJ; Huss JM
    Gen Comp Endocrinol; 2018 Nov; 268():110-120. PubMed ID: 30114400
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Peroxisome proliferator-activated receptors and the control of inflammation.
    Cabrero A; Laguna JC; Vázquez M
    Curr Drug Targets Inflamm Allergy; 2002 Sep; 1(3):243-8. PubMed ID: 14561188
    [TBL] [Abstract][Full Text] [Related]  

  • 66. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
    Sertznig P; Seifert M; Tilgen W; Reichrath J
    J Cell Physiol; 2007 Jul; 212(1):1-12. PubMed ID: 17443682
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation.
    Bugge A; Mandrup S
    PPAR Res; 2010; 2010():. PubMed ID: 20862367
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Expression and function of peroxisome proliferator-activated receptors in human melanocytes.
    Kang HY; Chung E; Lee M; Cho Y; Kang WH
    Br J Dermatol; 2004 Mar; 150(3):462-8. PubMed ID: 15030328
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PPAR Ligands Containing Stilbene Scaffold.
    Fantacuzzi M; De Filippis B; Amoroso R; Giampietro L
    Mini Rev Med Chem; 2019; 19(19):1599-1610. PubMed ID: 31161987
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Physiological and therapeutic roles of peroxisome proliferator-activated receptors.
    Berger J; Wagner JA
    Diabetes Technol Ther; 2002; 4(2):163-74. PubMed ID: 12079620
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Physiological and pharmacological function of PPARs].
    Takahashi N; Kawada T
    Nihon Yakurigaku Zasshi; 2001 May; 117(5):319-27. PubMed ID: 11411341
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Application of the human hepatoblastoma cell lines inducibly expressing peroxisome proliferator-activated receptors (PPARs)].
    Tachibana K
    Yakugaku Zasshi; 2007 Aug; 127(8):1223-9. PubMed ID: 17666873
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
    Aleshin S; Strokin M; Sergeeva M; Reiser G
    Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship.
    Ohashi M; Oyama T; Nakagome I; Satoh M; Nishio Y; Nobusada H; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
    J Med Chem; 2011 Jan; 54(1):331-41. PubMed ID: 21128600
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PPARs as targets for metabolic and cardiovascular diseases.
    Cheng PT; Mukherjee R
    Mini Rev Med Chem; 2005 Aug; 5(8):741-53. PubMed ID: 16101410
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
    Gani OA
    Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation.
    Ram VJ
    Prog Drug Res; 2003; 60():93-132. PubMed ID: 12790340
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PPARs and the cardiovascular system.
    Hamblin M; Chang L; Fan Y; Zhang J; Chen YE
    Antioxid Redox Signal; 2009 Jun; 11(6):1415-52. PubMed ID: 19061437
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism.
    Smith SA
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):1086-90. PubMed ID: 12440979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.